Catecholaminergic Polymorphic Ventricular Tachycardia

should be counseled on the need for appropriate cautions (eg, availability of an automated external defibrillator during training and competition). For patients who have had symptoms (eg, syncope, cardiac arrest) or who have demonstrated VF or sustained VT, the primary treatment is high doses of a long-acting beta-blocker, preferably one without intrinsic sympathomimetic activity (eg, nadolol, slow-release propranolol). If beta-blockade is ineffective, flecainide may be useful both for its sodium channel and ryanodine receptorâ€“blocking effects. Implantable cardioverter-defibrillators (ICDs) are used for patients with CPVT who survived cardiac arrest or who have VT despite antiarrhythmic pharmacotherapy. Refractory cases are treated with left cardiac sympathetic denervation and/or arrhythmia substrate ablation. Follow-up typically involves repeated exercise testing, but the predictive value is only moderate. Patients who are asymptomatic (including relatives identified by genetic testing) should also moderate their physical activity and receive beta-blocker therapy.
